Search NASA⌕ Search

Engineering topics

Makarashvili, V.

Publications and source records attributed to Makarashvili, V..

Production of Medical Isotopes with Electron Linacs

Radioisotopes play important roles in numerous areas ranging from medical treatments to national security and basic research. Radionuclide production technology for medical applications has been pursued since the early 1900s both commercially and in nuclear science centers. Many medical isotopes are now in routine production and are used in day-to-day medical procedures. Despite these advancements, research is accelerating around the world to improve the existing production methodologies as well as to develop novel radionuclides for new medical appli-cations. Electron linear accelerators (linacs) represent a unique method for the production of radioisotopes. Even though the basic technology has been around for decades, only recently have electron linacs capable of producing photons with sufficient energy and flux for radioisotope production become available. Housed in Argonne Nation-al Laboratory’s Low Energy Accelerator Facility (LEAF) is a newly upgraded 55 MeV/25-kW electron linear ac-celerator, capable of producing a wide range of radioiso-topes. This talk will focus on the work being performed for the production of the medical isotopes 99Mo (99Mo/99mTc generator), 67Cu, and 47Sc.

Cu-67↗

Results of four one-day electron-accelerator irradiations of enriched Mo-100 targets for the production of Mo-99

A series of four one-day irradiations was conducted with 100 Mo-enriched disk targets. After irradiation, the enriched disks were removed from the target and dissolved. The resulting solution was processed using a NorthStar RadioGenix™ 99m Tc generator either at Argonne National Laboratory or at the NorthStar Medical Radioisotopes facility. Runs on the RadioGenix system produced inconsistent analytical results for 99m Tc in the Tc/Mo solution. These inconsistencies were attributed to the impurities in the solution or improper column packing. During the irradiations, the performance of the optic transitional radiation (OTR) and infrared cameras was tested in high radiation field. The OTR cameras survived all irradiations, while the IR cameras failed every time. The addition of X-ray and neutron shielding improved camera survivability and decreased the number of upsets.

38 RADIATION CHEMISTRY, RADIOCHEMISTRY, AND NUCLEA↗

Accelerator-Driven Production of Fission 99Mo

I{esults al'e reportecl for the procluction of eeMo l'rom the accelerator-clriveu subcritical fission of a low enriohed uranir¡m (Ltju) aqì.reous solution. Phase I ol'these experiments used a 5 L r.rranyl sulfate solution with a eeMo encl-of-irracliation produotion limit of 2 Ci. The separation, recovery, and pulification of eeMo were demonstrated Lrsing the recyclecl solution. Fission product paltitioriing tl'ends will be shown for the recovery colutt'ttt, concentratiorl colurnn, and LE,U Modified Cintichem prooess. The results fi'om a 1.4 Ci oeMo production run, where the fìnal product was seut to GE Flealthcare for testing, will be highlightecl. The information gained cluring Phase ì lias signilìcantly irnpacted the clesign and implernentation of Phase ll. Phase II focuses on an end-of-irradiation ploduction of 20 Ci of eeMo and a fissior'ì power density similar to the production fàcility in a20 L LìlU uranyl sulfate solution.

accelerator↗

Precise absolute γ -ray and β - -decay branching intensities in the decay of Cu 29 67

In this work, absolute γ-ray emission probabilities in the β - decay of 67 Cu were measured by means of γ-ray and β - -decay singles and β - -γ coincidences. The new results, together with the known decay scheme of 67 Cu , were used to determine absolute β - -decay branching intensities. The present data differ significantly from previously published values. In addition, the half-life of the I π = 1/2 - isomer in 67 Zn was measured as T 1/2 = 9.37(4) μs, in a good agreement with earlier measurements. Lastly, from the analysis of the Fermi–Kurie plots, Q β - ( g.s.) = 560.3 (10) keV was deduced, which differs from the previously measured value of 577(8) keV but is in good agreement with Q β - ( g.s.) = 561.3 (15) keV recommended in the latest Atomic Mass Evaluation.

73 NUCLEAR PHYSICS AND RADIATION PHYSICS↗

Chemical Processing Activities for 99 Mo production by (γ,n) and (n,γ) reactions using enriched 100 Mo and 98 Mo targets

Recently, several technologies were proposed for the production of 99 Mo/ 99 mTc without the use of 235 U targets. These technologies offer the potential for a lower-cost alternative to fission produced 99 Mo, but with lower yields of 99 Mo or 99 mTc. Enriched 98 Mo or 100 Mo targets are necessary for economic production of several thousand Ci of 99 Mo. Argonne, in collaboration with Los Alamos and Oak Ridge National Laboratories, are assisting NorthStar Medical Technologies in the development of a domestic supply of 99 Mo. NorthStar’s short-term plan is to produce 99 Mo using 98 Mo(n,)γ 99 Mo reaction at MURR, and their long-term solution is to produce 99 Mo using an electron accelerator via the 100 Mo(,γn) 99 Mo reaction. The latest experimental results from irradiation of enriched 100 Mo targets, large-scale dissolution studies, and development of enriched material recycle process will be presented

37 INORGANIC, ORGANIC, PHYSICAL, AND ANALYTICAL CH↗

Radio of Nitrate and Sulfate Solutions

Argonne National Laboratory (Argonne) is assisting two of the potential domestic producers, Babcock and Wilcox Technical Services Group (B&W) and Morgridge Institute for Research (MIR), in the development of a Mo-99 production pathway that do not use high enriched uranium (HEU), as part of the National Nuclear Security Administration (NNSA) Global Threat Reduction Initiative’s (GTRI) program. B&W is developing the Medical Isotope Production System (MIPS); in this system, the Mo-99 is produced in a low enriched uranium (LEU)-fueled aqueous homogenous reactor (AHR) by the fission of U-235. MIR is developing the Subcritical Hybrid Intense Neutron Emitter (SHINE), which creates Mo-99 by neutroninduced fission of LEU in a sub-critical aqueous solution. One difference between the two is that MIR is considering aqueous uranyl-sulfate as the target solution, while B&W is planning to use aqueous uranyl nitrate as the fuel solution.

Kalensky, M.↗

Design of the Phase-2 Target for Mini-SHINE/MIPS Experiments

Under the National Nuclear Security Administration’s Global Threat Reduction Initiative (GTRI), Argonne National Laboratory (Argonne) is assisting three potential domestic producers to develop and implement molybdenum-99 (Mo-99) production in the United States without the use of highly enriched uranium (HEU). Two of the potential domestic producers are Babcock and Wilcox Technical Services Group (B&W) and Morgridge Institute for Research (MIR). B&W is developing the Medical Isotope Production System (MIPS). In this system, the Mo-99 is produced in an LEU-fueled Aqueous Homogenous Reactor (AHR) by the fissioning of uranium-235 (U-235). The MIPS consists of an AHR containing a low enriched uranium (LEU) solution, a molybdenum-extraction system utilizing a chromatographic column, and a reactor off-gas and solution-control systems. The use of AHRs presents an attractive alternative to the conventional target-irradiation method for producing Mo-99 because the fuel solution itself is used to produce Mo-99, eliminating the need for targets. AHRs also operate at a much lower power level than that required for a traditional reactor. The three areas of Argonne research and development (R&D) are (1) radiolytic-gas generation in the fuel solution, (2) effects of fission and radiation on reactor-solution chemistry, and (3) development and optimization recovery of molybdenum from the irradiated fuel solution.

Chemerisov, S.↗